Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Advanced NSCLC With EGFR Mutation”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Testing effectiveness (Phase 2)Active Not RecruitingNCT03831932
What this trial is testing

Telaglenastat Hydrochloride and Osimertinib in Treating Patients With EGFR-Mutated Stage IV Non-small Cell Lung Cancer

Who this might be right for
Advanced Lung Non-Small Cell CarcinomaMetastatic Lung Non-Small Cell CarcinomaStage IV Lung Cancer AJCC v8
National Cancer Institute (NCI) 22
Large-scale testing (Phase 3)Study completedNCT01774721
What this trial is testing

ARCHER1050: A Study of Dacomitinib vs. Gefitinib in 1st-Line Treatment Of Advanced NSCLC.

Who this might be right for
Non-small Cell Lung Cancer With EGFR-Activating Mutations
Pfizer 452
Testing effectiveness (Phase 2)Active Not RecruitingNCT05078931
What this trial is testing

Evaluate Pembrolizumab Plus Lenvatinib in PD-L1 Positive TKI Resistant NSCLC Patients

Who this might be right for
NSCLC
Shanghai Chest Hospital 35
Testing effectiveness (Phase 2)Looking for participantsNCT06962865
What this trial is testing

A Phase Ⅱ Study of RC108 in Combination With Furmonertinib for the First-line Treatment of EGFR-Mutated Combined MET-Positive Unresectable Locally Advanced or Recurrent Metastatic NSCLC

Who this might be right for
Non-Small Cell Lung Cancer
RemeGen Co., Ltd. 80
Not applicableStudy completedNCT04031898
What this trial is testing

Treatment Patterns, Outcomes and Testing in EGFRm NSCLC Patients With EGFR TKI 1L Across Europe (REFLECT)

Who this might be right for
Lung Cancer
AstraZeneca 896
Not applicableLooking for participantsNCT07348965
What this trial is testing

Pulsatile High-dose Furmonertinib in EGFR-mutant NSCLC With Leptomeningeal Metastasis

Who this might be right for
NSCLC (Advanced Non-small Cell Lung Cancer)Leptomeningeal MetastasisFurmonertinib+1 more
Guangzhou University of Traditional Chinese Medicine 42
Testing effectiveness (Phase 2)Study completedNCT02108964
What this trial is testing

A Phase I/II, Multicenter, Open-label Study of EGFRmut-TKI EGF816, Administered Orally in Adult Patients With EGFRmut Solid Malignancies

Who this might be right for
Advanced Non-small Cell Lung Cancer
Novartis Pharmaceuticals 225
Testing effectiveness (Phase 2)UnknownNCT05068024
What this trial is testing

FWD1509 in Adults With Non-Small Cell Lung Cancer

Who this might be right for
Carcinoma, Non-Small-Cell Lung
Forward Pharmaceuticals Co., Ltd. 30
Testing effectiveness (Phase 2)Looking for participantsNCT06668103
What this trial is testing

Clinical Study of Combination Therapy With ABSK043 and Firmonertinib

Who this might be right for
Non-Small Cell Lung Cancer With EGFR Mutation
Abbisko Therapeutics Co, Ltd 54
Testing effectiveness (Phase 2)Study completedNCT03861156
What this trial is testing

D-0316 in Patients With EGFR Positive Non Small Cell Lung Cancer

Who this might be right for
Solid TumorNSCLCEGFR T790M
InventisBio Co., Ltd 290
Large-scale testing (Phase 3)Study completedNCT04206072
What this trial is testing

D-0316 Versus Icotinib in Patients With Locally Advanced or Metastatic EGFR Sensitising Mutation Positive NSCLC

Who this might be right for
Non-Small Cell Lung CancerEGFR Gene Mutation
Betta Pharmaceuticals Co., Ltd. 362
Testing effectiveness (Phase 2)Not Yet RecruitingNCT06672068
What this trial is testing

TY-9591 With Chemotherapy as 1st Line Treatment in Patients With Mutated Epidermal Growth Factor Receptor NSCLC

Who this might be right for
NSCLC
TYK Medicines, Inc 60
Testing effectiveness (Phase 2)Study completedNCT05258279
What this trial is testing

Lenvatinib in Combination With Carboplatin Pemetrexed and Pembrolizumab for NSCLC With EGFR Mutations

Who this might be right for
Non-squamous Non-small-cell Lung CancerEGFR Activating Mutation
Juntendo University 30
Testing effectiveness (Phase 2)Study completedNCT04824079
What this trial is testing

Keynatinib in Treated Patients With NSCLC and Brain Metastases

Who this might be right for
Non-Small Cell Lung Cancer With EGFR MutationBrain Metastases
Medolution Ltd. 16
Testing effectiveness (Phase 2)Looking for participantsNCT07518160
What this trial is testing

JS212 Plus JS111 in EGFR-Mutant Advanced NSCLC: A Phase II Study

Who this might be right for
Locally Advanced, Metastatic, or Recurrent Non-small Cell Lung Cancer (NSCLC) Harboring Epidermal Growth Factor Receptor (EGFR) Mutations
Shanghai Junshi Bioscience Co., Ltd. 35
Large-scale testing (Phase 3)UnknownNCT04870190
What this trial is testing

Almonertinib Versus Osimertinib in the Patients With EGFR Mutations in Advanced NSCLC With Brain Metastases

Who this might be right for
NSCLC
Shanghai Chest Hospital 232
Testing effectiveness (Phase 2)Active Not RecruitingNCT05256290
What this trial is testing

Phase 1/2 Study of Silevertinib (BDTX-1535) in Patients With Glioblastoma or Non-Small Cell Lung Cancer With EGFR Mutations

Who this might be right for
Non-Small Cell Lung CancerAdvanced Non-Small Cell Squamous Lung CancerMetastatic Lung Non-Small Cell Carcinoma+7 more
Black Diamond Therapeutics, Inc. 200
Not applicableStudy completedNCT01723878
What this trial is testing

ASPET Study: An Observational Study of Tarceva (Erlotinib) in First Line in Patients With Advanced Non-Small Cell Lung Cancer Harbouring EGFR Activating Mutations

Who this might be right for
Non-Squamous Non-Small Cell Lung Cancer
Hoffmann-La Roche 144
Early research (Phase 1)UnknownNCT04448379
What this trial is testing

Efficacy and Safety of JMT101 Combined With Afatinib (or Osimertinib) in Patients With Non-Small Cell Lung Cancer

Who this might be right for
Locally Advanced or Metastatic Non-Small Cell Lung Cancer
Shanghai JMT-Bio Inc. 48
Testing effectiveness (Phase 2)Not Yet RecruitingNCT06182761
What this trial is testing

Sunvozertinib Combined With Anlotinib in Local Advanced or Metastatic Non-small Cell Lung Cancer

Who this might be right for
NSCLC
Shanghai Zhongshan Hospital 45
Next Page